Drug Trial Radar · NCT04580745
Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Sep 23, 2020
Primary completion
Mar 31, 2021
Study completion Apr 12, 2021
Sponsor
- Lead sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Industry
- Sponsor type
- Industry
- First posted
- Oct 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase 1a randomized, double-blind, placebo-controlled study to evaluate single and multiple ascending doses of MORF-057 in healthy subjects.
Conditions
- Healthy Volunteers
Interventions
MORF-057Drug
SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of MORF-057. Food Effect: Subjects will receive single dose administration of MORF-057 in fed and fasted states. MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of MORF-057.
Placebo for MORF-057Drug
SAD: Subjects will be assigned to one of five planned dose cohorts and receive single doses of placebo. MAD: Subjects will be assigned to one of three planned dose cohorts and receive multiple doses of placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events and safety signals observed during single and multiple ascending doses of MORF-057 administered orally to healthy adult subjectsTime frame: Day -1 to Day 28
- Maximum Plasma Concentration (Cmax) of MORF-057 in a fed stateTime frame: Day -1 to Day 28
- Time to Reach Cmax (Tmax) of MORF-057 in a fed stateTime frame: Day -1 to Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medpace
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.